Compare

Johnson & Johnson vs Pfizer

MonkScore ranges and fundamentals, side by side

Key facts

Johnson & Johnson and Pfizer: key facts

  • In fiscal 2025, Johnson & Johnson reported revenue of $94.2B and net income of $26.8B.
  • In fiscal 2025, Pfizer Inc. reported revenue of $62.6B and net income of $7.8B.
  • Johnson & Johnson's revenue grew 4.6% a year from fiscal 2021 to fiscal 2025.
  • Pfizer Inc.'s revenue fell 6.3% a year from fiscal 2021 to fiscal 2025.
  • Johnson & Johnson's free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • Pfizer Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • In the twelve months to 27 September 2026, Johnson & Johnson reported revenue of $99.3B and net income of $16.1B.
  • In the twelve months to 28 June 2026, Pfizer Inc. reported revenue of $63.7B and net income of $4.3B.

Side by side

Johnson & Johnson and Pfizer, side by side

Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.

FigureJohnson & JohnsonNYSE:JNJPfizer Inc.NYSE:PFE
MonkScore
MonkScore range70–80as of October 202620–30as of October 2026
Sector rank175 of 628 in Healthcare520 of 628 in Healthcare
How this score is madeDisclaimer
Profile
SectorHealthcareHealthcare
IndustryDrug Manufacturers - GeneralDrug Manufacturers - General
Latest fiscal year
Revenue$94.2BFY 2025$62.6BFY 2025
Net income$26.8BFY 2025$7.8BFY 2025
Free cash flow$19.7BFY 2025$9.1BFY 2025
Operating cash flow$24.5BFY 2025$11.7BFY 2025
Total debt$47.9BFY 2025$67.4BFY 2025
Cash$19.7BFY 2025$1.1BFY 2025
Last 12 months
Revenue$99.3Bto 27 September 2026$63.7Bto 28 June 2026
Net income$16.1Bto 27 September 2026$4.3Bto 28 June 2026
Free cash flow$20.6Bto 27 September 2026$11.0Bto 28 June 2026
Operating cash flow$26.2Bto 27 September 2026$13.4Bto 28 June 2026
Total debt$44.7Bto 27 September 2026$63.2Bto 28 June 2026
Cash$16.9Bto 27 September 2026$976.0Mto 28 June 2026

MonkStreet provides research, not investment advice.